<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03708588</url>
  </required_header>
  <id_info>
    <org_study_id>18-078_18-911</org_study_id>
    <nct_id>NCT03708588</nct_id>
  </id_info>
  <brief_title>Chewed Versus Integral Pill of Ticagrelor</brief_title>
  <official_title>Chewed Versus Integral Pill of Ticagrelor in All Patients Undergoing Percutaneous Coronary intervention--a Platelet Reactivity and Patient Outcomes Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aurora Health Care</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aurora Health Care</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis The primary question the investigators propose to answer is whether all patients&#xD;
      undergoing PCI with stent deployment who receive chewed ticagrelor will demonstrate more&#xD;
      rapid drug absorption and decreased platelet reactivity as compared to integral pill form 1&#xD;
      hour after drug administration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis The primary question the investigators propose to answer is whether all patients&#xD;
      undergoing PCI with stent deployment who receive chewed ticagrelor will demonstrate more&#xD;
      rapid drug absorption and decreased platelet reactivity as compared to integral pill form 1&#xD;
      hour after drug administration.&#xD;
&#xD;
      Secondary Hypotheses:&#xD;
&#xD;
        1. Major adverse cardiac and cerebrovascular event (MACCE) rate at 30 days and 1 year.&#xD;
&#xD;
             1. Death&#xD;
&#xD;
             2. Repeat myocardial infarction&#xD;
&#xD;
             3. Need for urgent revascularization&#xD;
&#xD;
             4. Cerebrovascular accident&#xD;
&#xD;
        2. Rate of stent thrombosis and in-stent stenosis at 30 days and 1 year.&#xD;
&#xD;
        3. Bleeding: Defined as major, minor, or minimal bleeding based on TIMI criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 19, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of pharmacodynamics</measure>
    <time_frame>1 hour</time_frame>
    <description>Measure platelet reactivity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Major adverse cardiac and cerebrovascular event MACCE</measure>
    <time_frame>30 days</time_frame>
    <description>Measure events such as: death, repeat myocardial revascularization, cerebrovascular accident, stent thrombosis, in-stent stenosis and bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Major adverse cardiac and cerebrovascular event MACCE</measure>
    <time_frame>1 year</time_frame>
    <description>Measure events such as: death, repeat myocardial revascularization, cerebrovascular accident, stent thrombosis, in-stent stenosis and bleeding.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>Experimental: Chewed ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Ticagrelor chewed pills. The loading dose will be administered as soon as possible by Catheterization Lab staff after a baseline PRU level is drawn and before the end of the PCI. Patients will be asked to chew, but not swallow, allowing for sublingual absorption. (Loading dose 180mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator: Integral pill</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Ticagrelor integral pills. The loading dose will be administered as soon as possible by Catheterization Lab staff after a baseline PRU level is drawn and before the end of the PCI. Patients will swallow the loading dose followed by 25-50mL of water. (180mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Chewed</description>
    <arm_group_label>Experimental: Chewed ticagrelor</arm_group_label>
    <other_name>Brilinta</other_name>
    <other_name>Brilique</other_name>
    <other_name>Possia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Integral</description>
    <arm_group_label>Active Comparator: Integral pill</arm_group_label>
    <other_name>Brilinta</other_name>
    <other_name>Brilique</other_name>
    <other_name>Possia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        â€¢ All patients presenting to the cardiac catheterization lab for percutaneous coronary&#xD;
        intervention.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years or Age &gt;89 years&#xD;
&#xD;
          -  Known coagulopathy, bleeding diathesis, or active bleeding&#xD;
&#xD;
          -  History of recent gastrointestinal or genitourinary bleed within 2 months&#xD;
&#xD;
          -  Known chronic therapy with clopidogrel, prasugrel, or ticagrelor&#xD;
&#xD;
          -  Major surgery within last 6 weeks&#xD;
&#xD;
          -  History of intracranial bleed or intracranial neoplasm&#xD;
&#xD;
          -  Suspected aortic dissection&#xD;
&#xD;
          -  Severe hemodynamic instability, cardiogenic shock&#xD;
&#xD;
          -  Life expectancy &lt;1 year&#xD;
&#xD;
          -  Known severe liver or renal disease&#xD;
&#xD;
          -  Known HIV treatment&#xD;
&#xD;
          -  Any use of GP IIb-IIIa inhibitors 48-hours before the procedure or any use during the&#xD;
             procedure&#xD;
&#xD;
          -  Any use of Cangrelor during or after the procedure&#xD;
&#xD;
          -  Hemoglobin &lt;10 g/dL, PLT &lt;100x10^9/L&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Known allergy to study medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas F Wilson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aurora Health Care</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aurora Health Care, St. Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 10, 2018</study_first_submitted>
  <study_first_submitted_qc>October 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2018</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aurora Health Care</investigator_affiliation>
    <investigator_full_name>Thomas F. Wilson</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Ticagrelor</keyword>
  <keyword>Stent</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

